Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2015 | Pages:
47 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Achillion Pharmaceuticals, Inc. - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Achillion Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Achillion Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Achillion Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Achillion Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Achillion Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Achillion Pharmaceuticals, Inc.'s pipeline products Reason To Buy - Evaluate Achillion Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Achillion Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Achillion Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Achillion Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Achillion Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Achillion Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Achillion Pharmaceuticals, Inc. Snapshot 5 Achillion Pharmaceuticals, Inc. Overview 5 Key Information 5 Key Facts 5 Achillion Pharmaceuticals, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Achillion Pharmaceuticals, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Achillion Pharmaceuticals, Inc. - Pipeline Products Glance 10 Achillion Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 10 Phase II Products/Combination Treatment Modalities 10 Phase I Products/Combination Treatment Modalities 11 Achillion Pharmaceuticals, Inc. - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Discovery Products/Combination Treatment Modalities 13 Achillion Pharmaceuticals, Inc. - Drug Profiles 14 ACH-3102 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 sovaprevir 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 ACH-3422 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 deldeprevir 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 ACH-3080 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 ACH-3107 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 ACH-CFDIS 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Small Molecule to Inhibit DNA gyrase for Bacterial Infections 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Small Molecules for Immunology 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Small Molecules to Inhibit Complement Factor D for Acute Hemolytic Uremic Syndrome 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Small Molecules to Inhibit Complement Factor D for AMD 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Small Molecules to Inhibit Complement Factor D for Myasthenia Gravis 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Small Molecules to Inhibit DNA gyrase for Bacterial Infections 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Achillion Pharmaceuticals, Inc. - Pipeline Analysis 28 Achillion Pharmaceuticals, Inc. - Pipeline Products by Target 28 Achillion Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 29 Achillion Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 30 Achillion Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 31 Achillion Pharmaceuticals, Inc. - Recent Pipeline Updates 32 Achillion Pharmaceuticals, Inc. - Dormant Projects 41 Achillion Pharmaceuticals, Inc. - Discontinued Pipeline Products 42 Discontinued Pipeline Product Profiles 42 ACH-2928 42 Achillion Pharmaceuticals, Inc. - Company Statement 43 Achillion Pharmaceuticals, Inc. - Locations And Subsidiaries 45 Head Office 45 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 46 Disclaimer 47
List of Tables
Achillion Pharmaceuticals, Inc., Key Information 5 Achillion Pharmaceuticals, Inc., Key Facts 5 Achillion Pharmaceuticals, Inc. - Pipeline by Indication, 2015 7 Achillion Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 8 Achillion Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 9 Achillion Pharmaceuticals, Inc. - Phase II, 2015 10 Achillion Pharmaceuticals, Inc. - Phase I, 2015 11 Achillion Pharmaceuticals, Inc. - Preclinical, 2015 12 Achillion Pharmaceuticals, Inc. - Discovery, 2015 13 Achillion Pharmaceuticals, Inc. - Pipeline by Target, 2015 28 Achillion Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015 29 Achillion Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015 30 Achillion Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015 31 Achillion Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015 32 Achillion Pharmaceuticals, Inc. - Dormant Developmental Projects,2015 41 Achillion Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2015 42
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
